Only if you're looking for a highly speculative buy to hold for the long term.
News & Analysis: Ocugen, Inc.
Its vaccine candidate will have to stand out in a tough playing field.
These stocks have been unstoppable since late December -- but will they stay that way?
Is it all just hype, or is this a biotech stock you should consider buying?
OCGN earnings call for the period ending December 31, 2020.
They're off to a good start.
Each of these players has dropped about 40% or more in recent weeks.
Ocugen has set record highs this month on news regarding COVID-19 vaccine Covaxin. Is it too late to get in on the stock?
This point will determine just how much Ocugen can profit from its potential coronavirus vaccine.
Results are encouraging -- but are they strong enough to stand out?